Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 24;13:1756284820979765. doi: 10.1177/1756284820979765

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2020

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Serial fecal calprotectin levels in IBD patients during VDZ induction, specified for patients with and without endoscopic response (A), endoscopic remission (B) and histological remission (C)Number of patients (FC) with/without endoscopic response at week 0: 26/18, week 2: 25/17, week 4: 25/16, week 8: 26/16, week 16: 24/16Number of patients (FC) with/without endoscopic remission at week 0: 13/31, week 2: 12/30, week 4: 13/28, week 8: 13/29, week 16: 13/27Number of patients (FC) with/without histological remission at week 0: 12/23, week 2: 10/23, week 4: 11/21, week 8: 11/22, week 16:11/20Boxplots describe median and first and third quartile of FC at the predefined serial time points

*Indicates statistically different FC levels between patients with and without response or remission the two evaluated groups in analysis as tested by the Wilcoxon Rank testFC; fecal calprotectin